Tamoxifen in advanced breast cancer

pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response

“…In general, the capacity of pNR-2 immunohistochemical staining to predict hormonal response on relapse is similar to that described for oestrogen receptor and progesterone receptor either singly or in combination in other series (Mourisden et al, 1978;Osborne et al, 1980), where objective responses to endocrine therapy were obtained after relapse in more than half of the receptor positive tumours but were rare in receptor negative tumours. pNR-2 immunohistochemical staining has advantages over detection of both receptors in that it is applicable to routinely formalin fixed and processed paraffin embedded histological material, eliminating the need to prepare cytosol.…”

A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd

“…correlation of response to dominant site, age, disease free interval etc.) are similar to those reported in reviews of published clinical trials (Mouridsen et al, 1978;Patterson, 1981) suggesting that our patient sample was representative of the population normally treated. The lower response rate in patients with primary tumours, irrespective of dose, is probably a function of the size of the lesion (5cm by definition of "inoperable"), making the criterion for partial response (more than 50% decrease in the product of perpendicular diameters) more difficult to achieve because of the increased tumour burden.…”

“…The only other direct comparison of two dosages was a non-randomised study (Lerner et al, 1976) in which the results were considered inconclusive. A review of 19 major clinical trials (Mouridsen et al, 1978) suggested that a dose of 40mg daily was associated with a higher overall response than 20mg daily (39% versus 28%) but this conclusion needs confirming in a prospective randomised trial.…”

Tamoxifen, serum lipoproteins and cardiovascular risk

“…Objective tumour responses are seen in some 30% of all cases in pre-and postmenopausal patients. The mean duration of tumour remission is 11 to 12 months, but responses lasting a few years are no exception (Mouridsen et al, 1978).…”